Please ensure Javascript is enabled for purposes of website accessibility

Why Agile Therapeutics Stock Is Getting Crushed Today

By George Budwell – Feb 27, 2020 at 11:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Agile's stock can't seem to find a bottom, despite a major regulatory approval earlier this month.

What happened

Shares of the early commercial stage biotech Agile Therapeutics (AGRX -8.12%) are in a tailspin Thursday morning. The drugmaker's stock is down by 20.5% as of 10:12 a.m. EST today.

Following this latest downward move, Agile's stock has now lost over a third of its value since the start of February. That's not exactly the outcome shareholders were hoping for after the company got the green light from the Food and Drug Administration (FDA) for its weekly contraceptive patch Twirla roughly two weeks ago on Feb. 14

A man getting punched in the face.

Image source: Getty Images.

So what

Agile's collapse since Twirla's approval is the result of three headwinds:

  1. There is still tremendous uncertainty surrounding the commercial opportunity offered by Twirla. Wall Street has the product's sales coming in at a respectable $58.6 million in 2021, which would definitely be a decent haul for a company with a market cap hovering around $174 million at present. To reach that point, however, the company has to work out Twirla's reimbursement status with payers and hire a sales team. That's a lot to ask of a company new to the game of marketing and selling a healthcare product. 
  2. Agile doesn't have the strongest balance sheet. The company did recently raise capital, but it still may not have a long enough cash runway to reach cash-flow-positive status. That implies more capital raises could be in store over the next year or so. 
  3. Finally, this is just a bad day for small-cap biotech stocks in general, due to the threat of COVID-19, the disease caused by the novel coronavirus. Nearly all of these stocks are in the red this morning. 

Now what

Is Agile stock a bargain at these levels? The good news is that the bottom can't be that far off. Twirla's long-term commercial opportunity is simply too great for this stock to continue to fall, especially at this breakneck pace. So, if you're comfortable with volatility, it might be a good idea to buy some shares on this latest dip. 

George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Agile Therapeutics, Inc. Stock Quote
Agile Therapeutics, Inc.
AGRX
$0.28 (-8.12%) $0.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.